Sep 07, 2022 05:46 PM (GMT+8) · EqualOcean
Biocreatech (Chinese: 百葵锐生物) completed the Series Pre-A round of financing worth tens of millions of CNY. The round was led by Wanlian Daoyi (Tianjin) Venture Capital Partnership (Chinese: 天津万联道一创业投资合伙企业) and Xingtuo Capital (Chinese: 星陀资本). Focusing on efficient biosynthesis in skin health, pet intestinal health treatment, and biopesticides, Biocreatech has built a whole-state chain synthetic biology platform based on protein precision design and protein molecular machine technology. By using an intelligent automated high-throughput screening system overlaid with efficient gene editing technology, Biocreatech is able to modularize the R&D and production process of biosynthesis and significantly improve the efficiency of synthesis.